Clinical characteristics of colitis induced by taxane-based chemotherapy

This item is provided by the institution :
Hellenic Society of Gastroenterology   

Repository :
Annals of Gastroenterology   

see the original item page
in the repository's web site and access all digital files if the item*



Clinical characteristics of colitis induced by taxane-based chemotherapy (EN)

Thirumurthi, Selvi
Chen, Ellie
Tan, Dongfeng
Wang, Yinghong
Wei, Dongguang
Altan, Mehmet
Barcenas, Carlos H.
Khurana, Shruti
Morris, Van K.
Mallepally, Niharika
Abu-Sbeih, Hamzah

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

2019-12-27


Background Limited data are available concerning the clinical features of toxic gastrointestinal (GI) effects of taxane-based therapy. We describe the clinical, endoscopic and histologic features of taxane-induced colitis. Methods This retrospective study included cancer patients who received taxane therapy and underwent colonoscopy for GI symptoms from 2000-2018. Results Of the 45,527 patients who received taxane therapy during the study period, 76 (0.2%) met the inclusion criteria. Most patients (54%) received paclitaxel, 37% docetaxel, and 9% nab-paclitaxel. The median time from taxane therapy initiation to colitis symptom onset was 31 days. The median duration of colitis symptoms was 30 days. Colitis treatment comprised immunosuppressive therapy in 8 patients (11%), antibiotics in 17 (22%), antimotility agents in 18 (24%), and octreotide or somatostatin in 2 (3%). Thirty-five patients (46%) required hospitalization and seven (9%) required admission to the intensive care unit (ICU). Endoscopy revealed mucosal ulceration in 19 patients (25%), nonulcerative inflammation in 32 (42%), and normal findings in 25 (33%). Seventeen patients (22%) had features of lymphocytic colitis. One patient had spontaneous colonic perforation that required surgical intervention. Colitis symptoms recurred in 7 patients (9%) after initial improvement. Patients who received nab-paclitaxel developed GI toxicity earlier (P=0.003), required colitis-related hospitalization more frequently (P=0.005), and received intravenous fluids more frequently (P=0.025), compared with patients who received other taxanes. Conclusions Taxane-related colitis can present with significant inflammation on colonoscopy, and in a minority of patients as microscopic colitis. Taxane-induced colitis, although uncommon, can lead to ICU admission and colonic perforation. Keywords Taxane, paclitaxel, docetaxel, chemotherapy, colitis, diarrhea, gastrointestinal adverse events Ann Gastroenterol 2020; 33 (1): 59-67 (EN)


English

Hellenic Society of Gastroenterology (EN)


1792-7463
1108-7471
Annals of Gastroenterology; Volume 33, No 1 (2020); 59 (EN)

Copyright (c) 2019 Annals of Gastroenterology (EN)




*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)